Founded only a year ago, cancer drug firm Cleave Biosciences attracted a whopping $42 million in a Series A financing, expected to be disclosed Tuesday, to push its lead programs into the clinic.Founded only a year ago, cancer drug firm Cleave Biosciences attracted a whopping $42 million in a Series A financing, expected to be disclosed Tuesday, to push its lead programs into the clinic. Read More
Unither Virology LLC, a subsidiary of United Therapeutics Corp., won a potential $45 million contract from the National Institutes of Health (NIH) for preclinical studies of an antiviral glycobiology drug candidate to treat viruses such as dengue and influenza. Read More
New research published this week showed that pulmonary fibrosis has underlying molecular mechanisms that are similar to those of liver fibrosis. Read More
Stopped up for nearly a decade, the pipeline for hepatitis C virus (HCV) is flowing with hope these days as several biotechs advance new candidates that could make treatment easier to stomach. Read More
Insmed Inc., of Monmouth Junction, N.J., said the FDA is continuing its clinical hold on Phase III trials of Arikace (liposomal amikacin for inhalation) in cystic fibrosis (CF) patients with pseudomonas lung infections. The company said it has not yet received a response from the agency regarding the hold previously placed on Phase III trials of Arikace in patients with nontuberculous mycobacterial lung disease. Read More
Zosano Pharma Inc., of Fremont, Calif., and Asahi Kasei Pharma Corp. (AKP), of Tokyo, entered a long-term collaboration to develop, commercialize and supply a weekly transdermal patch formulation of Teribone (teriparatide acetate), AKP's formulation of human parathyroid hormone for the treatment of osteoporosis patients with a high risk of fracture. Read More
